Form 4: Nuvation Bio Inc. CEO Acquires 2,000,000 Stock Options
SEC Form 4 Filing
Nuvation Bio Inc.'s CEO, David Hung, reports the acquisition of 2,000,000 stock options with an exercise price of $1.97, vesting over four years.
Summary
- David Hung, the President and CEO of Nuvation Bio Inc., filed a Form 4 on March 4, 2025.
- The filing reports a transaction that occurred on February 28, 2025, where Hung acquired 2,000,000 stock options.
- The exercise price of these options is $1.97.
- The options vest as to 25% on the one-year anniversary of February 28, 2025, and then monthly over the subsequent 36 months, contingent upon continuous service.
- The expiration date for these options is February 27, 2035.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing regarding stock option grants.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as the CEO, ensuring fair markets.
Stakeholder Impact
- The granting of stock options to the CEO aligns his interests with those of the shareholders, potentially incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of transaction: CEO acquired 2,000,000 stock options. |
| 02/28/2025 | First vesting date: 25% of the options vest one year from this date. |
| 02/27/2035 | Expiration date of the stock options. |
| 03/04/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.